<DOC>
	<DOCNO>NCT01371110</DOCNO>
	<brief_summary>Obsessive-Compulsive Disorder ( OCD ) chronic disable anxiety disorder lead cause worldwide disability present significant public health problem . Treatment option limit many OCD patient fail respond completely quickly standard treatment , include pharmacotherapy psychotherapy . At time , patient fail respond treatment serotonergic drug , augment antipsychotic agent , behavioral therapy , additional treatment option aside deep brain stimulation . Therefore , despite advance current pharmacological behavioral treatment , utility serotonergic drug , likely neurotransmitter system involve target system may increase treatment efficacy . Despite little evidence serotonergic dysfunction OCD , significant evidence glutamatergic dysregulation may contribute development progression disorder . Also , preliminary study suggest glutamatergic modulators ( i.e . riluzole d-cycloserine ) , particularly agent act NMDA receptor ( i.e . memantine ) , may useful OCD . The NMDA antagonist , ketamine , demonstrate rapid effect deliver single intravenous ( IV ) dose depressed patient . Therefore , objective current study investigate safety efficacy single dose IV ketamine treatment-resistant OCD .</brief_summary>
	<brief_title>Intravenous Ketamine Treatment Obsessive-Compulsive Disorder</brief_title>
	<detailed_description>This study test safety efficacy single intravenous ( IV ) dose N-methyl-D-aspartate ( NMDA ) glutamate receptor antagonist , ketamine , treatment-resistant OCD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male female patient , 2165 year Women childbearing potential must agree use medically accept mean contraception duration study Primary diagnosis ObsessiveCompulsive Disorder assess SCIDP , symptoms least 1 year ( Patients meet criterion OCD require medication free psychotropics aside SSRIs need benzodiazepine taper . Prior study entry , proscribe psychotropics taper , subject must SSRI least 8 week change dose least 4 week throughout study . However , subject allow use benzodiazepine need throughout study . ) History failure respond least two ( 2 ) adequate pharmacotherapy trial CBT OCD Subjects must score â‰¥ 21 YBOCS Screening , remission Treatment Day # 1 , Treatment Day # 2 Each subject must level understanding sufficient agree test examination require protocol must sign informed consent document Subjects must able identify family member , physician , friend participate Treatment Contract serve emergency contact . Women plan become pregnant within next six month , pregnant breastfeed NonEnglish speaker Any unstable medical illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease Clinically significant abnormal finding laboratory parameter , physical examination , ECG Lifetime history schizophrenia , schizoaffective disorder , bipolar disorder , mental retardation , pervasive developmental disorder Current evidence psychotic manic symptom Drug alcohol abuse dependence within precede 6 month Lifetime abuse dependence ketamine phencyclidine Patients judge study investigator high risk suicide Current use psychotropics SSRIs</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>OCD</keyword>
	<keyword>Obsessive-Compulsive Disorder</keyword>
	<keyword>ketamine</keyword>
	<keyword>treatment</keyword>
</DOC>